{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:45:58Z","timestamp":1761061558334,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014434","name":"Columbia University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalimaging.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Imaging"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clinimag.2021.11.029","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T01:49:48Z","timestamp":1638755388000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunotherapy related pericardial effusion on chest CT"],"prefix":"10.1016","volume":"82","author":[{"given":"Kathleen M.","family":"Capaccione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeeshan","family":"Toor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clinimag.2021.11.029_bb0005","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.jtho.2019.05.044","article-title":"Lung cancer incidence and mortality with extended follow-up in the national lung screening trial","volume":"14","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.clinimag.2021.11.029_bb0010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cllc.2013.04.010","article-title":"Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes","volume":"14","author":"Skrzypski","year":"2013","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1016\/j.clinimag.2021.11.029_bb0015","first-page":"93","article-title":"Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers","volume":"2","author":"Daraselia","year":"2012","journal-title":"Am J Cancer Res"},{"issue":"18_suppl","key":"10.1016\/j.clinimag.2021.11.029_bb0020","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7082","article-title":"Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database","volume":"24","author":"Navada","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5 Suppl.","key":"10.1016\/j.clinimag.2021.11.029_bb0025","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.12-2359","article-title":"Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Howington","year":"2013","journal-title":"Chest"},{"issue":"9687","key":"10.1016\/j.clinimag.2021.11.029_bb0030","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clinimag.2021.11.029_bb0035","first-page":"189","article-title":"Lung cancer: biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.clinimag.2021.11.029_bb0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clinimag.2021.11.029_bb0045","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"10.1016\/j.clinimag.2021.11.029_bb0050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"9652","key":"10.1016\/j.clinimag.2021.11.029_bb0055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clinimag.2021.11.029_bb0060","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clinimag.2021.11.029_bb0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.clinimag.2021.11.029_bb0070","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8002","article-title":"First-line crizotinib versus pemetrexed\u2013cisplatin or pemetrexed\u2013carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)","volume":"32","author":"Mok","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10072","key":"10.1016\/j.clinimag.2021.11.029_bb0075","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clinimag.2021.11.029_bb0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","article-title":"Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Ettinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"35","key":"10.1016\/j.clinimag.2021.11.029_bb0085","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clinimag.2021.11.029_bb0090","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clinimag.2021.11.029_bb0095","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinimag.2021.11.029_bb0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"issue":"2","key":"10.1016\/j.clinimag.2021.11.029_bb0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.clinimag.2021.11.029_bb0110","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clinimag.2021.11.029_bb0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers11030305","article-title":"Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features","volume":"11","author":"Porcu","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.clinimag.2021.11.029_bb0120","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab","volume":"3","author":"Tirumani","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"10.1016\/j.clinimag.2021.11.029_bb0125","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1148\/rg.2019190036","article-title":"Immune checkpoint inhibitor Therapy\u2013related pneumonitis: patterns and management","volume":"39","author":"Kalisz","year":"2019","journal-title":"Radiographics"},{"key":"10.1016\/j.clinimag.2021.11.029_bb0130","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920922033","article-title":"Association of immune-related pneumonitis with the efficacy of PD-1\/PD-L1 inhibitors in non-small cell lung cancer","volume":"12","author":"Cui","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.clinimag.2021.11.029_bb0135","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000217","article-title":"Immune-mediated pericarditis with pericardial tamponade during nivolumab therapy","volume":"41","author":"de Almeida","year":"2018","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.clinimag.2021.11.029_bb0140","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune checkpoint inhibitor-associated pericarditis","volume":"14","author":"Altan","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.clinimag.2021.11.029_bb0145","article-title":"Pericardial effusion under nivolumab: case-reports and review of the literature","volume":"7","author":"Saade","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.clinimag.2021.11.029_bb0150","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.200210-1154OC","article-title":"Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro","volume":"169","author":"Blanchet","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.clinimag.2021.11.029_bb0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.clinimag.2021.11.029_bb0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature","volume":"7","author":"Shaheen","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"10.1016\/j.clinimag.2021.11.029_bb0165","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/1759-7714.13149","article-title":"Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"10","author":"Komiya","year":"2019","journal-title":"Thorac Cancer"},{"issue":"153","key":"10.1016\/j.clinimag.2021.11.029_bb0170","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0058-2019","article-title":"Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer","volume":"28","author":"Cadranel","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.clinimag.2021.11.029_bb0175","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.clinimag.2021.11.029_bb0180","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.2000.1397","article-title":"Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer","volume":"83","author":"Moriya","year":"2000","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clinimag.2021.11.029_bb0185","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-019-03897-0","article-title":"Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study","volume":"84","author":"Kotake","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinimag.2021.11.029_bb0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fonc.2020.00070","article-title":"Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma-a retrospective study","volume":"10","author":"Hadash-Bengad","year":"2020","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clinimag.2021.11.029_bb0195","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/CMR.0000000000000669","article-title":"Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients","volume":"30","author":"Vera Aguilera","year":"2020","journal-title":"Melanoma Res"},{"issue":"32","key":"10.1016\/j.clinimag.2021.11.029_bb0200","doi-asserted-by":"crossref","first-page":"52436","DOI":"10.18632\/oncotarget.9420","article-title":"Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clinimag.2021.11.029_bb0205","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/clc.21967","article-title":"Vascular endothelial growth factor in malignant and benign pericardial effusion","volume":"35","author":"Karatolios","year":"2012","journal-title":"Clin Cardiol"}],"container-title":["Clinical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707121004605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707121004605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:49:17Z","timestamp":1760269757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899707121004605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":41,"alternative-id":["S0899707121004605"],"URL":"https:\/\/doi.org\/10.1016\/j.clinimag.2021.11.029","relation":{},"ISSN":["0899-7071"],"issn-type":[{"type":"print","value":"0899-7071"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy related pericardial effusion on chest CT","name":"articletitle","label":"Article Title"},{"value":"Clinical Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinimag.2021.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}